Epi-C (Epigenetic Compounds) is a new spin-off biotech company operating in the field of epigenetics.
One of our primary aims is to develop novel drugs with anti-cancer properties.
Epi-C performs small molecule screenings, as well as biological and molecular characterisation of drugs.
Epi-C patents pending:
Patent 1 - Immune-sensor for mobile detection of inquinants
Patent 2 - Use of integrated epigenome signature for acute leukemia patient’s stratification